Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2246137 | 0.84 | POLB (0.70) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL3380247 | 0.83 | POLB (0.68) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL28450939 | 0.83 | MEN1 (0.68) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL19334315 | 0.83 | MEN1 (0.64) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL5472507 | 0.81 | POLB (0.62) | MEN1KMT2AALDH1A1LMNAMAPK1 | |
| SCHEMBL17724619 | 0.80 | SNCA (0.58) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL19581635 | 0.80 | SNCA (0.58) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL13577033 | 0.80 | KMT2A (0.64) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL17724903 | 0.79 | CYP19A1 (0.61) | POLB | |
| SCHEMBL19581924 | 0.79 | CYP19A1 (0.61) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160143826-A1 | PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION | L'OREAL (FR) | 2016-05-26 | — | — | US | disclosed |
| US-20100144743-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF TYROSINE KINASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144743-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF TYROSINE KINASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008030795-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF TYROSINE KINASES | BOARDS OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144743-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF TYROSINE KINASES | ABL1, LCK, SRC | MEN1 3047/4885KMT2A 1620/4885ALDH1A1 3156/4885 |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | MEN1 1223/4885KMT2A 1132/4885ALDH1A1 1875/4885 |
| US-20160143826-A1 | PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION | KRT18, ARSA, SQOR | MEN1 4240/4885KMT2A 1157/4885ALDH1A1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.